A Nature Communications study led by Yang, Wu, and Jiang demonstrated that combining bacteriophages with conventional antibiotics eradicated refractory peritoneal dialysis–related peritonitis caused by Klebsiella pneumoniae in animal models. The combination outperformed antibiotics alone against multidrug‑resistant isolates. The work provides proof‑of‑concept for adjunctive phage therapy to overcome antibiotic resistance in severe, device‑associated infections. Authors detailed phage selection, synergy assays and in vivo efficacy, and discussed translational hurdles including phage manufacturing, regulatory frameworks, and host immune interactions. Next steps include safety and dosing studies, GMP‑grade phage development, and human trials to establish whether the synergy seen in animals translates into clinical benefit for patients with drug‑resistant peritonitis.